FY2027 EPS Estimates for CG Oncology Lifted by HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Analysts at HC Wainwright lifted their FY2027 earnings per share estimates for shares of CG Oncology in a research note issued to investors on Tuesday, April 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($1.84) per share for the year, up from their prior estimate of ($1.90). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s FY2028 earnings at $0.06 EPS.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million during the quarter.

CGON has been the subject of a number of other reports. Truist Financial upped their price objective on CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Piper Sandler upped their price objective on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Wedbush began coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Morgan Stanley set a $93.00 price objective on CG Oncology in a report on Friday, January 9th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $70.67.

CG Oncology Trading Down 0.5%

CGON opened at $68.56 on Thursday. The stock has a 50-day moving average price of $60.33 and a 200-day moving average price of $49.16. CG Oncology has a 12-month low of $16.17 and a 12-month high of $71.90. The stock has a market capitalization of $5.79 billion, a P/E ratio of -33.12 and a beta of 0.70.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new stake in CG Oncology during the 4th quarter valued at about $62,909,000. T. Rowe Price Investment Management Inc. purchased a new stake in CG Oncology during the 4th quarter valued at about $17,547,000. Invesco Ltd. boosted its holdings in CG Oncology by 10.9% during the 4th quarter. Invesco Ltd. now owns 38,140 shares of the company’s stock valued at $1,584,000 after acquiring an additional 3,761 shares during the period. ADAR1 Capital Management LLC boosted its holdings in CG Oncology by 3.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 258,139 shares of the company’s stock valued at $10,718,000 after acquiring an additional 9,222 shares during the period. Finally, XTX Topco Ltd purchased a new stake in CG Oncology during the 4th quarter valued at about $1,400,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director James Mulay sold 1,964 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.40% of the stock is owned by corporate insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.